| Primary |
| Product Used For Unknown Indication |
12.5% |
| Lung Infection |
8.3% |
| Sepsis |
8.3% |
| Tuberculosis |
8.3% |
| Urinary Tract Infection |
8.3% |
| Febrile Neutropenia |
6.3% |
| Osteitis |
6.3% |
| Pneumonia |
6.3% |
| Arthritis Bacterial |
4.2% |
| Diabetic Foot |
4.2% |
| Grand Mal Convulsion |
4.2% |
| Osteomyelitis |
4.2% |
| Pleural Effusion |
4.2% |
| Arthritis Infective |
2.1% |
| Budd-chiari Syndrome |
2.1% |
| Cellulitis |
2.1% |
| Diabetic Ulcer |
2.1% |
| Endocarditis |
2.1% |
| Hypertension |
2.1% |
| Liver Transplant |
2.1% |
|
| Epilepsy |
13.8% |
| Status Epilepticus |
10.3% |
| Drug Administration Error |
6.9% |
| Hepatic Enzyme Increased |
6.9% |
| Jaundice |
6.9% |
| Pyrexia |
6.9% |
| Anaemia |
3.4% |
| Cerebral Ischaemia |
3.4% |
| Confusional State |
3.4% |
| Death |
3.4% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
3.4% |
| Haemodialysis |
3.4% |
| Incorrect Dose Administered |
3.4% |
| Neurotoxicity |
3.4% |
| Osteomyelitis |
3.4% |
| Rales |
3.4% |
| Renal Failure |
3.4% |
| Toxicity To Various Agents |
3.4% |
| Tremor |
3.4% |
| Urticaria |
3.4% |
|
| Secondary |
| Product Used For Unknown Indication |
30.7% |
| Drug Use For Unknown Indication |
12.9% |
| Prophylaxis |
7.1% |
| T-cell Type Acute Leukaemia |
5.3% |
| Hypertension |
4.4% |
| Nasopharyngitis |
4.4% |
| Pneumonia |
4.0% |
| Tuberculosis |
3.6% |
| Infection Prophylaxis |
3.1% |
| Antibiotic Therapy |
2.7% |
| Antitussive Therapy |
2.7% |
| B Precursor Type Acute Leukaemia |
2.7% |
| Premedication |
2.7% |
| Urinary Tract Infection |
2.7% |
| Infection |
2.2% |
| Acute Myeloid Leukemia |
1.8% |
| Grand Mal Convulsion |
1.8% |
| Myeloid Leukaemia |
1.8% |
| Nausea |
1.8% |
| Pain |
1.8% |
|
| Fall |
8.8% |
| Monocytopenia |
8.8% |
| Pyrexia |
8.8% |
| Drug Hypersensitivity |
5.9% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
5.9% |
| Posterior Reversible Encephalopathy Syndrome |
5.9% |
| Rash |
5.9% |
| Toxic Encephalopathy |
5.9% |
| Unresponsive To Stimuli |
5.9% |
| Vomiting |
5.9% |
| White Blood Cell Count Increased |
5.9% |
| Agranulocytosis |
2.9% |
| Atrial Fibrillation |
2.9% |
| Cord Blood Transplant Therapy |
2.9% |
| Drug Level Increased |
2.9% |
| Immune Reconstitution Inflammatory Syndrome |
2.9% |
| Low Birth Weight Baby |
2.9% |
| Myoclonus |
2.9% |
| No Adverse Reaction |
2.9% |
| Pneumonia |
2.9% |
|
| Concomitant |
| Product Used For Unknown Indication |
20.2% |
| Prophylaxis |
14.8% |
| Infection Prophylaxis |
9.8% |
| Aplastic Anaemia |
7.5% |
| Bone Marrow Conditioning Regimen |
5.8% |
| Prophylaxis Against Graft Versus Host Disease |
5.6% |
| Antifungal Prophylaxis |
5.4% |
| Acute Myeloid Leukaemia |
5.2% |
| Premedication |
3.8% |
| Antiviral Prophylaxis |
3.2% |
| Prophylaxis Against Gastrointestinal Ulcer |
2.8% |
| Antibiotic Prophylaxis |
2.5% |
| Graft Versus Host Disease |
2.2% |
| Febrile Neutropenia |
2.1% |
| Acute Graft Versus Host Disease |
2.0% |
| Drug Use For Unknown Indication |
1.6% |
| Infection |
1.5% |
| Hypertension |
1.5% |
| Constipation |
1.2% |
| Insomnia |
1.2% |
|
| Pyrexia |
13.2% |
| White Blood Cell Count Decreased |
8.8% |
| Sepsis |
8.2% |
| Staphylococcal Sepsis |
8.2% |
| Febrile Neutropenia |
7.5% |
| Staphylococcal Infection |
6.3% |
| Acute Graft Versus Host Disease In Skin |
5.0% |
| Interstitial Lung Disease |
4.4% |
| Pseudomonal Sepsis |
4.4% |
| Stomatitis |
4.4% |
| Cystitis Haemorrhagic |
3.8% |
| Urinary Tract Infection |
3.8% |
| Infection |
3.1% |
| Therapeutic Response Decreased |
3.1% |
| Viral Haemorrhagic Cystitis |
3.1% |
| Acute Myeloid Leukaemia Recurrent |
2.5% |
| Cerebral Haemorrhage |
2.5% |
| Herpes Zoster |
2.5% |
| Platelet Count Decreased |
2.5% |
| Pulmonary Oedema |
2.5% |
|
| Interacting |
| Atrial Flutter |
25.0% |
| Pneumonia |
25.0% |
| Pulmonary Embolism |
25.0% |
| Pain |
12.5% |
| Pain In Extremity |
12.5% |
|
| Retroperitoneal Haematoma |
100.0% |
|
